CanadianCannabisWire LimeLight of The MONTH is
 

Lexaria Bioscience Corp.
(NASDAQ: LEXX)

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules.  DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 23 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

Investment Considerations

• Lexaria Bioscience Corp. has disruptive proprietary technology protected by a broad international patent portfolio.
• The company has been issued 23 patents in the U.S., European Union and other countries, with more than 50 patents pending around the world.
• Lexaria’s DehydraTECH technology has a vast worldwide, multi-billion-dollar total addressable market, including multiple rapid-growth segments like cannabinoid and noncombustible nicotine delivery.
• The company has licensed its fat-soluble active molecule delivery technology to multiple established companies for use in their products.
• Lexaria completed an uplisting to Nasdaq Capital Markets and an $11 million financing in January 2021.

Receive SMS Text Alerts from CanadianCannabisWire

Text "CCWIRE" to 77948

(US Mobile Phones Only)

Recent Coverage
 

InvestorNewsBreaks - Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Award for Oral Nicotine Compound Patent

March 8, 2022 9:45 AM

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has been granted an Australian patent titled “Compositions Infused with Nicotine Compounds and Methods of Use Thereof.” The patent expands Lexaria’s world patent portfolio to 24. According to the announcement, the patent expands the company’s international intellectual property rights to apply its proprietary DehydraTECH(TM) enhancement technology to most oral forms of nicotine delivery, which would include pills, tablets, lozenges, capsules, pouches, gums and sprays. In addition to covering different forms of delivery, the patent also includes an array of nicotine forms, such as free base nicotine, nicotine salts, polymer resins of nicotine and other forms of nicotine complexes. This is the first patent awarded from LEXX’s eighth patent family; a first patent in a new patent family often leads to additional patents granted in that same family. Lexaria noted that it has pending patent applications in other countries, including the United States. The company also noted nine patent claims have been granted the government of Australia.

About CanadianCannabisWire (CNW)

CanadianCannabisWire (CCW) is a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services. Leveraging a professional team of journalists and writers, CCW introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network of over 5,000 key distribution outlets. Cutting through information overload, CCW's innovative and proprietary systems clearly and succinctly deliver its clients much needed visibility, recognition and brand awareness. CCW is where news, content and information converge.